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Abstract Interest into the effects of carnosine on cellular
metabolism is rapidly expanding. The first study to dem-
onstrate in humans that chronic b-alanine (BA) supple-
mentation (*3–6 g BA/day for *4 weeks) can result in
significantly augmented muscle carnosine concentrations
([50%) was only recently published. BA supplementation
is potentially poised for application beyond the niche
exercise and performance-enhancement field and into other
more clinical populations. When examining all BA sup-
plementation studies that directly measure muscle carno-
sine (n = 8), there is a significant linear correlation
between total grams of BA consumed (of daily intake
ranges of 1.6–6.4 g BA/day) versus both the relative and
absolute increases in muscle carnosine. Supporting this, a
recent dose–response study demonstrated a large linear
dependency (R2 = 0.921) based on the total grams of BA
consumed over 8 weeks. The pre-supplementation baseline
carnosine or individual subjects’ body weight (from 65 to
90 kg) does not appear to impact on subsequent carnosine
synthesis from BA consumption. Once muscle carnosine is
augmented, the washout is very slow (*2%/week).
Recently, a slow-release BA tablet supplement has been
developed showing a smaller peak plasma BA concentra-
tion and delayed time to peak, with no difference in the
area under the curve compared to pure BA in solution.
Further, this slow-release profile resulted in a reduced
urinary BA loss and improved retention, while at the same
time, eliciting minimal paraesthesia symptoms. However,
our complete understanding of optimizing in vivo delivery
and dosing of BA is still in its infancy. Thus, this review
will clarify our current knowledge of BA supplementation
to augment muscle carnosine as well as highlight future
research questions on the regulatory points of control for
muscle carnosine synthesis.
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Introduction
Carnosine was first identified in beef muscle extract over
100 years ago by the Russian biochemist Gulewitsch
(Gulewitsch and Amiradzibi 1900). Given its high con-
centration in muscle it was suitably named, as carno
translated from Latin means ‘‘flesh/meat’’. The relatively
high concentration of carnosine in all vertebrate skeletal
muscle suggested that it likely serves a physiologically
imperative role and mounting evidence, especially over the
last several years, has provided more evidences for this.
Carnosine (b-alanyl-L-histidine) is made up of the pro-
teinogenic essential amino acid L-histidine and the natu-
rally occurring non-essential amino acid b-alanine (BA;
Fig. 1). The concentrations of histidine-containing dipep-
tides (HCD; e.g. carnosine, anserine, balenine) were first
quantified in human skeletal muscle in the mid-1970s
(Bergstrom et al. 1974), with carnosine being the only
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HCD in human skeletal muscle (Quinn et al. 1992), but
some sixfold lower than the carnosine content of thor-
oughbred race horses (Harris et al. 1990). Intra-human and
interspecies comparisons have shown strong positive cor-
relations between muscle buffering capacity, carnosine/
HCD levels and fast-twitch muscle percentage (Abe 2000;
Harris et al. 1990; Parkhouse et al. 1985). Already since the
mid-1980s, it has been known that sprinters and rowers, as
compared to marathon runners, have a significantly greater
percentage of Type II fast-twitch fibers, and accordingly,
greater muscle carnosine concentrations, muscle buffering
capacity and high-intensity exercise performance (Park-
house et al. 1985). Lastly since 2006, eight different studies
have clearly shown that prolonged BA supplementation
(1.6–6.4 g/day for [4 weeks) in humans results in a
40–65% increase in muscle carnosine content (Kendrick
et al. 2008, 2009; Harris et al. 2006; Hill et al. 2007);
Baguet et al. 2009, 2010; Derave et al. 2007; Stellingwerff
et al. 2011). Thus in recent years, our knowledge on BA-
supplemented muscle carnosine increases has developed
rapidly.
As evidenced by the diverse topical list of this journals
special edition (Derave and Sale 2011), the interest in the
effects of carnosine metabolism on prospective functions in
myocellular homeostasis and other clinical populations with
muscle myopathies or dysfunction are quickly expanding.
As extensively reviewed by Begum et al. (2005), primarily,
in vitro and pre-clinical research has suggested a multitude
of physiological roles for carnosine, including acting as an
antioxidant, a regulator of muscle excitation–contraction
coupling via increasing calcium sensitivity, a source of
histidine for histamine synthesis for wound healing, pro-
tecting proteins against glycation during aging. Given the
unquestionable role that muscle carnosine plays in aug-
menting intramuscular buffering (Abe 2000), recent in vivo
work has shown strong associations between increased
muscle carnosine and high-intensity exercise performance
(for reviews see: Sale et al. 2010; Derave et al. 2010; Artioli
et al. 2010). Further, as highlighted within this special issue,
the efficacy of carnosine and/or BA supplementation to
augment muscle carnosine has also been linked to clinical
populations, such as Type II diabetics (Gualano et al. 2011)
and the elderly (del Favero et al. 2011). Similar to creatine
supplementation in humans which has demonstrated effi-
cacy in a range of clinical and disease state populations
(Tarnopolsky 2011), BA supplementation leading to aug-
mented muscle carnosine concentrations is potentially
poised for applications beyond the niche role of intra-
muscular buffering to enhance high-intensity exercise per-
formance. Thus, having a sound understanding of the
optimal in vivo delivery and dosing of BA supplements to
augment muscle carnosine is necessary. Correspondingly,
this review will highlight our current knowledge on muscle
specific dose–responses; whether baseline levels of muscle
carnosine impact subsequent increases; examine the post-
BA supplementation washout of carnosine; as well as
identify future research questions based on the points of
regulation of carnosine synthesis. Taken together, this
review hopes to elucidate and clarify the BA prescriptive
application to augment muscle carnosine.
Fig. 1 Schematic of the points
of regulation for carnosine/
b-alanine delivery and
subsequent skeletal muscle
carnosine synthesis
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Points of regulation for b-alanine delivery
and carnosine synthesis
Given that the first human study to successfully augment
muscle carnosine via BA supplementation only occurred in
2006 (Harris et al. 2006), and given the large species dif-
ferences in carnosine metabolism (Abe 2000), our under-
standing of all the points of regulation for BA delivery and
carnosine synthesis in humans is only starting to emerge.
As with any amino acid/protein, a given content is the
result of the equilibrium between synthesis and degrada-
tion/elimination. Thus, carnosine loading results in situa-
tions where adequate substrates (BA and L-histidine) result
in greater carnosine-synthesis rates as compared to degra-
dation rates. Conversely, carnosine washout will result
when degradation/elimination exceeds the synthesis (see
‘‘Muscle carnosine washout’’). Although there are many
tissues rich in carnosine, including kidney, olfactory tissue
in the brain and reproductive organs (Boldyrev and Severin
1990), this review will primarily focus on skeletal muscle
carnosine. Muscle carnosine synthesis appears to be pri-
marily driven by sarcoplasmic BA availability, and thus the
three main regulatory steps to consider include: (1) plasma
BA delivery, (2) BA transport into the muscle, and (3) the
activity of muscle carnosine synthase (CARNS).
Humans have evolved processes to synthesis endogenous
BA in the liver from the degradation of uracil (Fritzson
1957), but given that vegetarians have lower muscle car-
nosine contents (Everaert et al. 2011) optimal dietary
delivery of BA (primarily meat or supplementation) is
required for significant plasma BA delivery for muscle
carnosine synthesis. BA transport across the gut is accom-
plished by the H?-coupled amino-acid transporter PAT1/
SLC36A1, which is also known as the imino-acid carrier
(Thwaites and Anderson 2007). In humans, it appears that
BA is readily transported across the gastrointestinal tract
(Harris et al. 2006), and thus, this step does not appear to
limit muscle carnosine synthesis. Contrary to rodents
(Sauerhofer et al. 2007), humans have a highly active serum
carnosinase (CN1; Teufel et al. 2003), as the intact carno-
sine dipeptide is rapidly hydrolyzed to its constituent amino
acids with complete hydrolysis within *3 h (Gardner et al.
1991). A recent paper has also demonstrated that females
have a higher CN1 activity compared to males (Everaert
et al. 2011). It could be hypothesized that a lower serum
CN1 activity, as found in males, might cause a longer period
of elevated circulating plasma carnosine resulting in
increased muscle carnosine transport and synthesis, which
is supported by the fact that two recent papers have found
higher muscle carnosine contents in males than females
(Everaert et al. 2011; Baguet et al. 2011a).
Following plasma carnosine hydrolysis by CN1 to
L-histidine and BA, or direct BA supplementation, BA can
then be transported to target tissues. L-Histidine in muscle and
plasma is high compared to the low concentrations of BA, and
transport of BA into the muscle cell is via a b-amino-acid
transporter that is strongly dependent on sodium and chloride
and has a BA transporter Km of *40 lM (Bakardjiev and
Bauer 1994). However, these transport data were generated
via embryonic chicken-muscle cell cultures, and thus, caution
should be taken when extrapolating to humans, as this data
should be confirmed using human myocyte preparations. In
humans in normal physiological situations, the concentration
of plasma BA is below the muscle transport Km of 40 lM
(Decombaz et al. 2011). Therefore, it could be hypothesized
that sarcoplasmic BA delivery is the rate-limiting factor for
muscle carnosine synthesis via CARNS (Fig. 1). Both peptide
transporter 2 (PEPT2/SLC15A2; Lu and Klaassen 2006;
Dieck et al. 1999) and the taurine transporter (TauT/SLC616;
Tomi et al. 2008), have been shown to transport BA in several
rodent and cell-culture preparations, but remain to be clearly
identified as the primary BA transporter in human skeletal
muscle. Correspondingly, a recent conference abstract
showed in humans that BA supplementation-induced increa-
ses in muscle carnosine resulted in the opposite and com-
pensatory changes in muscle taurine content (Harris 2010).
This finding presumably was a result of competitive inhibition
of taurine transport by BA, lending support to key role that the
taurine transporter (TauT) plays in muscle carnosine and
taurine contents in humans.
Once BA is transported to the muscle sarcolemma, car-
nosine synthesis results from BA and ample sarcoplasmic
L-histidine by CARNS. Recently, Drozak et al. (2010), using
recombinant human protein, have cloned and identified
human CARNS, showing that L-histidine exhibits an enzyme
Km (*37 lM) four-times greater than BA. However,
beyond this single paper, limited research in humans has
been completed. Interestingly, a recent paper did demon-
strate a down-regulation of CARNS mRNA in just 5 weeks
when subjects were placed on a vegetarian diet (Baguet et al.
2011b), suggesting that BA sarcoplasmic availability has an
important impact on CARNS expression. In summary, many
of the points of regulation involved in BA delivery and
carnosine synthesis appear to have been identified (Fig. 1).
However, additional human research is required to fully
substantiate all points of regulation and to elucidate the
impact that increased BA availability and/or changing car-
nosine contents could have on each key step of regulation.
For more information please refer to Baguet et al. (2012) and
Harris et al. (2012) in this carnosine special edition.
Plasma kinetics of b-alanine consumption in vivo
Acute oral administration of BA ([800 mg) has consistently
been shown to cause transient (*60–90 min) paraesthesia,
Carnosine synthesis and washout 59
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which has been described, depending on the dose and
individual, as mild to severe ‘‘pins and needles’’ and ‘‘itching’’
sensations, which appears linked to plasma BA kinetics
(Harris et al. 2006). The mechanism(s) responsible for
these paraesthesia symptoms are not yet completely
understood, as at least five different BA receptor sites have
been identified that could be responsible for sensitization of
nociceptive neurons and the associated paraesthesia side-
effects (Crozier et al. 2007; Tiedje et al. 2010). For further
information, the interested reader is directed to a primary
study published in this special edition by our research
group examining the effect of altered BA plasma kinetics,
via consumption of slow versus fast release BA tablets, on
subsequent paraesthesia symptoms and urinary spillover in
humans (Decombaz et al. 2011).
In the first series of studies in humans, it was found that
single BA doses greater than *10 mg BA/kg body weight
(BW; *800 mg/dose), caused increasing moderate to
severe paraesthesia symptoms (Harris et al. 2006).
Accordingly, to circumvent undesired paraesthesia, many
initial BA dosing studies utilized multiple 800 mg BA
doses (sometimes up to eight individual doses) throughout
the day to deliver an efficacious daily BA dose for muscle
carnosine synthesis (Kendrick et al. 2008, 2009). However,
Harris et al. (2006) also examined delivering BA in a
concentrated chicken broth, a more complex food matrix
that would slow gastric emptying. Interestingly, even at a
high dose of 40 mg/kg BW (*3.2 g of BA), when BA was
delivered in 640 ml of chicken broth the peak plasma BA
was 50% lower, with a 50 min later time to peak as com-
pared to a 40 mg/kg BW pure BA supplement. Impor-
tantly, the former demonstrated no reported paraesthesia
symptoms, while in the latter treatment, subjects reported
significant symptoms, demonstrating that BA-associated
paraesthesia symptoms were related to either/both peak
plasma BA concentration and time to peak. Analogous to
drug pharmacology, increasingly, more evidences have
shown that altered pharmacokinetics of active ingredients
in complex food matrices can have considerable impact on
in vivo functional outcomes, such as food matrix beta-
glucan slowing the release of creatine and causing signif-
icantly less urinary creatine excretion (Deldicque et al.
2008). As highlighted within this journal, a ‘slow-release’
BA supplement not only eliminates all paraesthesia
symptoms (no measured paraesthesia symptom differences
between ‘slow-release’ BA and placebo) but also results in
one-third of the urinary spillover of BA over a 6 h post-
supplementation period (Decombaz et al. 2011). Further-
more, given the serial blood and symptom measurements in
this study, a comprehensive BA plasma kinetics to par-
aesthesia symptoms appraisal was possible. Consequently,
it appears that paraesthesia symptoms are more coupled to
the rate of plasma BA increase rather than the peak
concentration, as paraesthesia symptoms from pure BA
supplementation were greatest at 15 min with a BA con-
centration of 82 lmol/L, despite the fact that peak values
actually reached *225 lmol/L at 30 min. Despite lower-
ing the plasma peak, these ‘slow-release’ BA formulations
still reach effective plasma concentrations that are above
the BA transporter Km of *40 lM (Bakardjiev and Bauer
1994), as supported by a recent dose–response publication
from our laboratory, demonstrating highly efficacious
muscle carnosine synthesis with a ‘slow-release’ supple-
ment (Stellingwerff et al. 2011).
Only a single study has examined whether chronic
supplementation of BA with concurrently increasing
muscle carnosine concentrations can impact on sub-
sequent paraesthesia (Stellingwerff et al. 2011). Since
carnosine requires free histidine during synthesis, it
might be hypothesized that prolonged BA supplementa-
tion causing increases in carnosine may impact upon
L-histidine availability for histamine production and release
(Flancbaum et al. 1990), and subsequent histamine-like
reactions. However, this study showed no effect of acute
or chronic ‘slow-release’ BA supplementation on par-
aesthesia symptoms or blood clinical chemistry and
hematology measures over the 8-week supplementation
period (total BA consumed was 134.4 g; Stellingwerff
et al. 2011).
More researches need to be completed to fully charac-
terize the mechanism(s) responsible for the paraesthesia
symptoms found in humans with acute high dose BA
supplementation. However, paraesthesia can be circum-
vented with ‘slow-release’ BA tablets that not only elimi-
nate paraesthesia, but also allow for an easier and more
practical BA supplementation protocol, as twice the dose
can be acutely consumed (*1.6 vs. 0.8 g of pure BA)
without any significant side-effects. In addition, by elimi-
nating perceived paraesthesia side-effects, ‘slow-release’
BA supplements allow for optimal blinding of subjects in
future performance based studies.
Carnosine synthesis via beta-alanine supplementation
Despite muscle carnosine having a long scientific history of
being associated with improved buffering and performance
(Parkhouse et al. 1985; Harris et al. 1990), it was not until
1999 that the hypothesis that muscle carnosine contents
could be augmented via oral supplementation of its two
constituent amino acids (L-histidine and b-alanine) was
tested by Dunnett and Harris (1999). In this study, they
found that 100 mg/kg BW/day of b-alanine with 12.5
mg/kg BW/day of L-histidine supplemented to thoroughbred
racehorses (equivalent to *7 g BA/day in humans) over
30 days significantly increased the carnosine content of the
60 T. Stellingwerff et al.
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gluteus medius in five of six tested horses. Their major
conclusion from this paper was that ‘‘changes in muscle
carnosine concentrations appeared to be influenced by
beta-alanine bioavailability’’ (Dunnett and Harris 1999).
This conclusion was influenced by the fact that the con-
centration of L-histidine in muscle and plasma is high
compared to the low concentrations of BA (\2 lM plasma
BA), and transport of BA into the muscle cell is via a
highly specific b-amino-acid transporter with a Km of
*40 lM (Bakardjiev and Bauer 1994). Seven years later,
Harris and co-workers (2006) extended these initial find-
ings in thoroughbred racehorses by being the first to show
that prolonged BA supplementation (*3–6 g/day over
4 weeks) in humans also causes significant increases in
muscle carnosine content (*40–65%). Since this seminal
paper, every human study thus far has demonstrated sig-
nificant increases ([40%) in muscle carnosine during a
chronic BA-supplementation protocol (1.6–6.4 g/day for
[4 weeks) via either quantification of muscle biopsies
(Kendrick et al. 2008, 2009; Harris et al. 2006; Hill et al.
2007) or 1H-MRS, magnetic resonance spectroscopy
(MRS) analysis (Baguet et al. 2009, 2010; Derave et al.
2007; Stellingwerff et al. 2011). Thus, the capacity to
increase muscle carnosine from BA supplementation in
humans appears to be a very robust and reproducible
finding. All of these studies are highlighted in Fig. 2, which
correlates the percent increase in muscle carnosine versus
the total BA consumed at the time of the carnosine
quantification.
There is certainly considerable variability between
published studies when examining the absolute carnosine
concentrations (mmol/kgww) or the relative (% change) or
absolute increases after BA supplementation (Fig. 2). This
variability is due to both physiological and methodological
reasons. Probably the number one determinate of carnosine
content is the individual fiber type distribution, with Type
II ‘fast-twitch’ fibers containing nearly about double the
carnosine content as compared to Type I ‘slow-twitch’
(Harris et al. 1998), with large differences between indi-
viduals (Parkhouse et al. 1985). This in turn could have an
impact on the ability of individual fibers to synthesize
carnosine, although data thus far appears to show that
despite fast-twitch fibers having a greater initial carnosine
content, all fibers (Type I or Type IIa; Hill et al. 2007) and
muscle groups (Baguet et al. 2009; Stellingwerff et al.
2011) appear equally responsive to carnosine loading via
BA supplementation. As reviewed by Derave et al. (2010)
other physiological mechanisms that could be responsible
for the variability in loading and/or washout may be the
age, sex or background dietary intake of BA (e.g., vege-
tarians) of each individual. Further, it appears that for a
given total BA consumed, the percent increase in carnosine
is greater in muscle biopsy and biochemical extraction
studies than compared to 1H-MRS methods (Fig. 2). This is
not unexpected, as the absolute carnosine values can vary
due to measurement location (skeletal muscle type) and
methodological differences. An obvious explanation for
this apparent discrepancy could be the fact that in all four
Fig. 2 Correlation of all published studies between the relative
percent increases in muscle carnosine as compared to the total
b-alanine consumed by subjects (between 1.6 and 6.4 g BA/day). The
data represents 31 different muscle carnosine measurements across
different durations of BA supplementation (thus different total
consumed BA); different muscle groups (e.g., soleus, gastronemius
or tibialis anterior via 1H-MRS); different muscle fibers (e.g., Type I
vs. Type IIa via muscle biopsy and biochemical extraction) and
different training states (trained vs. untrained leg). Solid lines
compare 1H-MRS versus biopsy carnosine quantification, and the
dotted line represents all studies together (data adapted from:
Kendrick et al. 2008, 2009; Harris et al. 2006; Hill et al. 2007;
Baguet et al. 2009, 2010; Derave et al. 2007; Stellingwerff et al. 2011)
Carnosine synthesis and washout 61
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biopsy studies the samples were taken from the m.vastus
lateralis (Harris et al. 2006; Kendrick et al. 2008, 2009;
Hill et al. 2007), while all the 1H-MRS data have been
obtained from m.tibialis anterior, m-soleus and/or m.gas-
trocnemius (Stellingwerff et al. 2011; Baguet et al. 2009,
2010; Derave et al. 2007). It has been shown in a recent
study (Stellingwerff et al. 2011) that even if the absolute
carnosine increases are identical between different muscle
groups, the relative increase varies due to the differences in
the baseline pre-supplementation levels. Therefore, since
biopsy and 1H-MRS data are from muscles with different
baseline carnosine contents; a systematic difference can be
expected. An additional explanation could be that it is
becoming increasingly obvious that metabolites can be
immobilized (e.g., bound to macromolecules) and are thus
not completely MR-visible. Thus, a potential methodo-
logical explanation could be limited visibility of all the
carnosine metabolites in 1H-MR spectra, causing a lower
carnosine measurement compared to biochemical extrac-
tion methods from biopsies, which would quantify all
mobile and immobilized metabolites. However, this may
not necessarily be a disadvantage for MRS, as the visible
metabolites may be the key metabolites involved in bio-
chemical reactions in the cell. Nevertheless, when taking
all eight studies together there is a strong positive corre-
lation between the percent increase in muscle carnosine
and the total amount of BA consumed. Accordingly, the
linear regression (Fig. 2) suggests that for a desired *50%
in muscle carnosine, a total of *230 g of BA must be
taken (within a daily consumption range of 1.6–6.4 g BA/
day).
This positive correlation was also strongly demonstrated
both in relative (% increase) and absolute (mmol/kgww
increase) terms in a comprehensive dose–response paper
that our laboratory recently published (Stellingwerff et al.
2011). The multiple BA doses and multiple carnosine
assessments in this study allowed for a univariate assess-
ment which clearly demonstrated a highly linear depen-
dency (R2 = 0.921) based on the total grams of BA
consumed, when either 1.6 or 3.2 g BA/day was consumed.
In this study, it was shown that a total consumption of
100 g BA increased the absolute carnosine levels by
2.01 mmol/kgww. Thus, the absolute BA/carnosine dose-
response is solely dependent upon the total grams of BA
consumed, and there is no impact on the muscle type or the
daily BA supplementation regime (within 1.6–6.4 g BA/
day; Fig. 2). These findings result in a greatly simplified
BA prescriptive application to augment muscle carnosine.
Moreover, the continued apparent linearity (or the non-
saturation) of this correlation suggests that maximal muscle
carnosine levels that are potentially attainable remains to
be identified via a long-term ([6 months) BA dosing study.
It also remains to be seen if it is ideal to recommend
absolute daily BA doses (g/day) or correct for lean body
mass or body weight (g/kg/day). As of yet, no investigation
has directly examined the impact that fat free mass (FFM)
might have on BA delivery and carnosine synthesis.
Previous data have shown that muscle creatine increases
are negatively correlated to high baseline-creatine values
(Harris et al. 1992), suggesting a saturation response. This
phenomena have helped to explain ‘responders’ and ‘non-
responders’, with individuals with low baseline creatine
being ideal ‘responders’ to creatine supplementation and
performance outcomes. Thus, it could be hypothesized that
individuals with low baseline carnosine [either from a low
percentage of Type II fibers (Baguet et al. 2011c; Park-
house et al. 1985; Harris et al. 1998) or vegetarians,
females or the elderly (Everaert et al. 2011)], might
respond more favorable to BA-supplemented increases in
muscle carnosine. However, contrary to this hypothesis,
Baguet et al. (2010) found a positive correlation between
high baseline muscle carnosine and the increase in muscle
carnosine after supplementation (n = 8), meaning the
higher the initial carnosine contents the greater the effect of
BA supplementation on subsequent carnosine synthesis.
However more recently, we found no effect (p = 0.342) of
baseline carnosine levels and subsequent increases in car-
nosine via BA supplementation in 21 subjects (Stel-
lingwerff et al. 2011). However, caution should be
exercised with both studies as there were a limited total
number of subjects, without a huge range of baseline car-
nosine variability and until it is determined what the
maximal attainable muscle carnosine levels are with pro-
longed BA supplementation (muscle saturation point)
correlations between baseline carnosine and increases in
carnosine are undoubtedly limited.
Finally, when considering all body tissues containing
carnosine that might be impacted by BA supplementation,
we have to also consider the brain. Some areas of the
human brain are also high in carnosine (e.g., olfactory
structures), with homocarnosine being the most abundant
type (Kohen et al. 1988), and given the relatively non-
invasive nature of 1H-MRS theoretically could be quanti-
fied. However, as of yet, no human studies have reported
whether BA supplementation can also impact upon brain
concentrations of carnosine and whether this has an impact
on performance and/or health outcomes.
Muscle carnosine washout
With the cessation of BA supplementation, carnosine
degradation and elimination prevails over the synthesis and
carnosine washout occurs. However, analogous to carno-
sine synthesis, the key points of regulation dictating
washout of muscle carnosine remain to be clarified.
62 T. Stellingwerff et al.
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Figure 3 is adapted from Baguet et al. (2009) and high-
lights the two published papers that have examined muscle
carnosine washout kinetics post BA-supplementation
quantified via 1H-MRS analysis (Stellingwerff et al. 2011;
Baguet et al. 2009), as well as an unpublished study using
muscle biopsy and subsequent biochemical quantification
of muscle carnosine (Harris, unpublished). Regardless of
the carnosine quantification method, the washout of aug-
mented skeletal muscle carnosine after the termination of
BA supplementation is very slow, as Fig. 3 shows a
washout time of *10–20 weeks. This slow washout rate
for carnosine is in stark contrast to augmented muscle
creatine, which has a washout of *4 weeks (Hultman et al.
1996) and is coherent with the net rate of muscle carnosine
synthesis being dependent on the total accumulative BA
dose, and relatively independent on the supplementation
duration (Stellingwerff et al. 2011). Furthermore, carnosine
washout appears to be linear in nature and does not feature
first-order exponential decay kinetics as found in many
enzyme-catalyzed reactions. However, only one of the
three studies strictly contradicts an exponential washout
(Baguet et al. 2009) while the other two (Harris, unpub-
lished; Stellingwerff et al. 2011) could be explained by
either a linear or an exponential washout, given the
experimental accuracy. Therefore, further studies are nee-
ded to unambiguously support this conclusion.
There appears to be considerable variability for the
length of washout time, as Baguet et al. (2009) showed
*10 weeks for washout, while Stellingwerff et al. (2011)
and the unpublished data from Harris demonstrated a
*15 to 20-week washout. This variability between
studies for calculated washout time is probably due to
some of the potential regulatory influences described
above regarding carnosine synthesis and degradation and
methodological considerations. Furthermore, it is well
established that due to continual daily exercise, athletes
have increased protein turnover rates (increases in both
synthesis and breakdown), and therefore to stay in
nitrogen balance athletes require twice the amount of
dietary protein intake compared to sedentary individuals
(Phillips and Van Loon 2011). Thus, it could be hypoth-
esized that individuals who habitually exercise may have
higher carnosine turnover rates which may impact upon
synthesis and washout profiles and variability between
studies, but needs to be addressed in future work. Nev-
ertheless, given the slow washout time-course of carno-
sine, any potential performance and/or health benefits
resulting from augmented muscle carnosine would appear
to be realized 4–6 weeks post-supplementation.
Future directions
Since 2006, there has been a marked increase of in vivo
human studies examining the effects of BA supplementa-
tion on muscle carnosine synthesis and the subsequent
impact this may have on clinical populations and perfor-
mance (for reviews see: Sale et al. 2010; Derave et al.
2010; Artioli et al. 2010). However, there are still many
questions that remain to completely elucidate the points of
regulation of carnosine synthesis, and ultimately, what the
optimal BA-dosing protocol and optimal muscle and/or
brain carnosine concentration for health and performance
are. Important future practical questions and research
inquiries are highlighted below:
• What is the peak attainable muscle carnosine, and once
peak carnosine levels are realized, will correlations
with baseline carnosine become more apparent? What
are the performance and health outcomes with ever
increasing muscle carnosine contents?
• Could ever increasing muscle carnosine contents ulti-
mately lead to significant decreases in muscle taurine
since they both share the same muscle transporter
(TauT)?
• Does baseline carnosine contents and subsequent BA
dose to carnosine synthesis response and/or peak
attainable muscle carnosine differ between different
populations and explain some of the variability in
responses? (e.g., old/young; disease states; trained/
untrained; male/female; fiber-type differences?)
• What impact do varying baseline carnosine contents
have on plasma carnosinase (CN1) activity on sub-
sequent muscle carnosine synthesis via BA supplemen-
tation, and vice versa? Does CN1 activity, and other
key enzymes and transporters, change with increasing
or decreasing muscle carnosine concentrations?
Fig. 3 Relative washout of muscle carnosine in weeks compared
to post-supplementation carnosine values (data adapted from:
Stellingwerff et al. 2011; Baguet et al. 2009)
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• What is the minimal dose of BA needed to maintain
augmented carnosine stores and could this be achieved
with high meat/turkey intake (similar to our ancestors)?
• Are there any interactions with other supplements/
nutrients that impact on delivery, uptake and/or carno-
sine synthesis (e.g., taurine)?
• Finally, is brain carnosine content also impacted from
BA supplementation?
When studying these remaining questions, it is impor-
tant to consider the need for human in vivo research. More
specifically, humans have highly active serum CN1
enzyme activity (Fig. 1; Teufel et al. 2003), in contrast to
rodents and some other mammals which lack serum car-
nosinase, and thus, have considerable amounts of plasma
carnosine (Sauerhofer et al. 2007). This, and other funda-
mental species differences (Abe 2000), will require that
nearly all of the mechanistic questions be ascertained via
human studies. Taken together, given the large potential for
augmented carnosine to positively impact health and sports
performance, our quest for knowledge regarding carnosine
metabolism must continue to evolve.
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